Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Diabetic Macular Edema
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus
- Type
- Interventional
- Phase
- Phase 2Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04429503
- Collaborators
- Bayer
- Investigators
- Study Director: Clinical Trial Management Regeneron Pharmaceuticals